MX340962B - Agentes de enlace a receptor de canabinoide, composiciones y metodos. - Google Patents

Agentes de enlace a receptor de canabinoide, composiciones y metodos.

Info

Publication number
MX340962B
MX340962B MX2014000141A MX2014000141A MX340962B MX 340962 B MX340962 B MX 340962B MX 2014000141 A MX2014000141 A MX 2014000141A MX 2014000141 A MX2014000141 A MX 2014000141A MX 340962 B MX340962 B MX 340962B
Authority
MX
Mexico
Prior art keywords
receptor binding
cannabinoid receptor
particle
compositions
methods
Prior art date
Application number
MX2014000141A
Other languages
English (en)
Other versions
MX2014000141A (es
Inventor
Bevier Jonathan
Original Assignee
Patchtek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Patchtek Inc filed Critical Patchtek Inc
Publication of MX2014000141A publication Critical patent/MX2014000141A/es
Publication of MX340962B publication Critical patent/MX340962B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ceramic Engineering (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)

Abstract

Se describe una composición que comprende un agente de enlace al receptor de canabinoide unido a una partícula para el tratamiento de condiciones de la piel. La partícula puede ser una nanopartícula, tal como celulosa nanocristalina. La partícula se puede modificar adicionalmente con porciones funcionales. Las propiedades de administración de fármacos se pueden modificar al recubrir las partículas o al usar vesículas para administrar el agente de enlace al receptor de canabinoide y la partícula Se puede usar un substrato para administrar la composición a la piel.
MX2014000141A 2011-07-05 2012-07-05 Agentes de enlace a receptor de canabinoide, composiciones y metodos. MX340962B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161504655P 2011-07-05 2011-07-05
US13/541,400 US8758826B2 (en) 2011-07-05 2012-07-03 Cannabinoid receptor binding agents, compositions, and methods
PCT/US2012/045613 WO2013006729A2 (en) 2011-07-05 2012-07-05 Cannabinoid receptor binding agents, compositions and methods

Publications (2)

Publication Number Publication Date
MX2014000141A MX2014000141A (es) 2015-03-20
MX340962B true MX340962B (es) 2016-07-27

Family

ID=47437703

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014000141A MX340962B (es) 2011-07-05 2012-07-05 Agentes de enlace a receptor de canabinoide, composiciones y metodos.

Country Status (9)

Country Link
US (2) US8758826B2 (es)
EP (2) EP2729123B8 (es)
JP (1) JP2014520817A (es)
KR (1) KR20140065387A (es)
CN (1) CN103796637A (es)
CA (1) CA2840907C (es)
DK (1) DK2729123T3 (es)
MX (1) MX340962B (es)
WO (1) WO2013006729A2 (es)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2547323B1 (en) 2010-03-17 2016-01-27 Novaliq GmbH Pharmaceutical composition for treatment of increased intraocular pressure
CA2834855C (en) 2011-05-25 2020-12-29 Novaliq Gmbh Topical pharmaceutical composition based on semifluorinated alkanes
FI130619B (en) 2011-11-15 2023-12-15 Upm Kymmene Corp Matrix for controlled release of bioactive substances
US9884027B2 (en) 2012-01-12 2018-02-06 Nanofiber Solutions, Inc. Nanofiber scaffolds for biological structures
AU2013263292B2 (en) 2012-05-16 2018-03-08 Maninder SANDHU Pharmaceutical compositions for the delivery of substantially water-insoluble drugs
AU2013314303B2 (en) 2012-09-12 2018-01-18 Novaliq Gmbh Semifluorinated alkane compositions
MX363182B (es) 2012-09-12 2019-03-13 Novaliq Gmbh Composiciones que comprenden mezclas de alcanos semifluorados.
EP3730929A1 (en) * 2013-08-19 2020-10-28 University Of Houston Phosphorescent reporters
CA2925468A1 (en) * 2013-09-26 2015-04-02 Ronald D. Sekura Topical treatments incorporating cannabis sp. derived botanical drug product
MA39708A (fr) * 2014-03-27 2021-03-31 Bird Rock Bio Inc Anticorps qui se lient au récepteur cannabinoïde 1 (cb1) humain
WO2015171445A1 (en) * 2014-05-06 2015-11-12 Mewa Singh Pharmaceutical compositions comprising hemp and turmeric to treat pain and inflammation
US9436682B2 (en) * 2014-06-24 2016-09-06 Google Inc. Techniques for machine language translation of text from an image based on non-textual context information from the image
US9907823B1 (en) 2014-11-07 2018-03-06 Eric H. Kuhrts Water-soluble phytocannabinoid formulations
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
CA2979184C (en) 2015-03-10 2020-09-08 Nanosphere Health Sciences, Llc Lipid nanoparticle compositions and methods as carriers of cannabinoids in standardized precision-metered dosage forms
WO2017011785A1 (en) 2015-07-15 2017-01-19 National Concessions Group Inc. Topical antiviral formulations and methods of using the same
US20170042791A1 (en) * 2015-08-11 2017-02-16 KannaInnovations LLC Topical compositions comprising hydroxy acids and cannabinoids for skin care
GB2542797A (en) * 2015-09-29 2017-04-05 Gw Pharma Ltd Use of cannabinoids in the treatment of inflammatory skin diseases
EP3495023B1 (en) 2015-09-30 2020-04-22 Novaliq GmbH Semifluorinated compounds and their compositions
BR112018006633A2 (pt) 2015-09-30 2018-10-23 Bird Rock Bio Inc anticorpos que se ligam ao receptor canabinóide 1 (cb1) humano
US11154513B2 (en) 2015-09-30 2021-10-26 Novaliq Gmbh Semifluorinated compounds
EP3370788A4 (en) 2015-11-02 2019-07-31 Nanofiber Solutions, LLC ELECTRO-spun fibers with contrast agents and method for producing same
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
AU2017333420A1 (en) 2016-09-28 2019-04-04 Novaliq Gmbh Compositions comprising a cannabinoid receptor binding ligand
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
JP7225104B2 (ja) * 2017-02-01 2023-02-20 ジービーエス グローバル バイオファーマ，インコーポレイテッド マスト細胞関連炎症障害又は好塩基球媒介炎症障害の治療のためのカンナビノイド含有複合混合物
US10898608B2 (en) 2017-02-02 2021-01-26 Nanofiber Solutions, Llc Methods of improving bone-soft tissue healing using electrospun fibers
IL268728B1 (en) * 2017-02-15 2024-05-01 Botanix Pharmaceuticals Ltd Formulations of cannabinoids for the treatment of acne
AU2018253944B2 (en) 2017-04-21 2022-09-15 Dermaliq Therapeutics, Inc. Iodine compositions
CN110997006A (zh) * 2017-05-08 2020-04-10 因美制药公司 眼部药物递送制剂
EP3621601A1 (en) 2017-05-12 2020-03-18 Novaliq GmbH Pharmaceutical compositions comprosing semifluorinated alkanes for the treatment of contact lense-related conditions
US20180333565A1 (en) * 2017-05-22 2018-11-22 Moshe Ein-Gal Pressure wave drug delivery
EP3630067A4 (en) * 2017-05-26 2021-08-11 Altum Pharmaceuticals Inc. BIPHASIC CANNABINOID ADMINISTRATION
CA3067542A1 (en) * 2017-06-19 2018-12-27 Syddansk Universitet Bacitracin and/or daptomycin combined with cannabidiol for treatment of bacterial infections
US10543176B2 (en) * 2017-06-20 2020-01-28 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
US11318179B2 (en) 2017-06-20 2022-05-03 Jessica Kado Topical formulation for binding to dermatological cannabinoid receptors
US20190054036A1 (en) * 2017-08-17 2019-02-21 Nanofiber Solutions, Inc. Electrospun fibers having a pharmaceutical and methods of making and using the same
US11484510B2 (en) * 2017-08-28 2022-11-01 Apirx Pharmaceutical Usa, Llc Method to treat vitiligo
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
US11896559B2 (en) 2017-10-04 2024-02-13 Novaliq Gmbh Opthalmic compositions comprising F6H8
AU2018352039B2 (en) * 2017-10-18 2024-03-14 Mor Research Applications Ltd. Cannabidiol and chitosan compositions and methods of using the same
CA3086357A1 (en) * 2017-12-18 2019-06-27 Nanostrips, Inc. Transmucosal delivery device and method of manufacturing same
CA3092914A1 (en) * 2018-03-05 2019-09-12 Solva, Llc Water-soluble phytocannabinoid formulations
US11397738B2 (en) * 2018-03-07 2022-07-26 Iguazio Systems Ltd. Stateless stream handling and resharding
CA3095873A1 (en) * 2018-04-05 2019-10-10 Steven Robert ERBST Therapeutic elastic bandage for modulating the endocannabinoid system
EP3773528B1 (en) 2018-04-09 2024-01-10 Portland Technology Holdings LLC Hemp extract for treatment of pain in animals
US20210228497A1 (en) * 2018-04-27 2021-07-29 Remy Biosciences, Inc. New Medical Devices, Delivery Vehicles and Manufacturing Thereof
EP3793542A4 (en) * 2018-05-14 2022-03-30 Buzzelet Development And Technologies Ltd TERPENE-ENRICHED CANNABINOID COMPOSITIONS AND THEIR USES IN THE TREATMENT OF INFECTIOUS DISEASES
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
EP3814315A1 (en) * 2018-06-28 2021-05-05 Symrise AG Synthesis of (+)-cannabinoids and their therapeutic effects
US11013715B2 (en) 2018-07-19 2021-05-25 Vertosa, Inc. Nanoemulsion hydrophobic substances
US11504416B2 (en) 2018-09-04 2022-11-22 Paw Power, Inc. Formulation with cannabinoids
CA3111870C (en) 2018-09-27 2022-04-12 Novaliq Gmbh Topical sunscreen formulation
ES2974839T3 (es) 2018-10-12 2024-07-01 Novaliq Gmbh Composición oftálmica para el tratamiento de la enfermedad de ojos secos
CA3077561A1 (en) 2018-10-15 2020-04-15 Amnon VARDI Slow release cannabinoids and products thereof
CA3117910A1 (en) * 2018-11-08 2020-05-14 Gbs Global Biopharma, Inc. Therapeutic nanoparticles encapsulating terpenoids and/or cannabinoids
JP2022507660A (ja) * 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム
WO2020123619A1 (en) 2018-12-11 2020-06-18 Nanofiber Solutions, Llc Methods of treating chronic wounds using electrospun fibers
CN117695226A (zh) 2018-12-11 2024-03-15 迪斯拉普申实验室公司 用于递送治疗剂的组合物及其使用方法和制备方法
US20200188298A1 (en) * 2018-12-14 2020-06-18 NuVessl, Inc. Method For Using Composition With Enhanced Passenger Molecule Loading
WO2020186246A1 (en) * 2019-03-13 2020-09-17 Ulagaraj Selvaraj Stabilized solid nanoparticle formulations of cannabinoids and cannabinoid analogs with reduced ostwald ripening for oral, inhalation, nasal and parenteral drug delivery
CA3040547C (en) * 2019-04-17 2021-12-07 Medcan Pharma A/S Cannabinoid lozenge formulation
US20220257778A1 (en) * 2019-06-24 2022-08-18 Diverse Biotech, Inc. Beta-Lactam-Cannabinoid Conjugate Molecules
MX2021016050A (es) * 2019-06-28 2022-02-21 Nexzol Pharma Inc Formulaciones transdermicas.
AU2021206021A1 (en) * 2020-01-08 2022-06-02 Société des Produits Nestlé S.A. Oral solid cannabinoid oil composition for treating gastrointestinal disorders
US20210259988A1 (en) * 2020-02-21 2021-08-26 Nanofiber Solutions, Llc Electrospun structures having a pharmaceutical and methods of making and using the same
AU2021232060A1 (en) * 2020-03-05 2022-10-27 University Of Miami Cannabidiol nanodrug formulations and methods for use the same
CA3181302A1 (en) * 2020-06-04 2021-12-09 Mahmoud Mohamed Abdrabo MOUSTAFA Rigid cannabidiol analogues as potent modulators of cannabinoid receptors and uses thereof
US11524040B2 (en) 2020-08-24 2022-12-13 Charlotte's Web, Inc. Composition for the treatment of acne
US20220096369A1 (en) * 2020-09-25 2022-03-31 Irwin C. Jacobs Compositions comprising cannabinoids and methods of use thereof
US20220241163A1 (en) * 2021-02-04 2022-08-04 Ariel Scientific Innovations Ltd. Preparation of hyaluronic acid cbd conjugates
DK202170171A1 (en) 2021-04-13 2022-10-19 Cs Medica As Hair serum and supplement
US20240219400A1 (en) * 2021-04-29 2024-07-04 Seer, Inc. Peptide decorated nanoparticles for enrichment of specific protein subsets
WO2023086903A1 (en) * 2021-11-10 2023-05-19 Nano Pharmasolutions, Inc. Cannabidiol nanoparticle compositions
US11660348B1 (en) 2022-02-01 2023-05-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
US11883499B2 (en) 2022-02-01 2024-01-30 Akos Biosciences, Inc. Cannabinoid conjugate molecules
WO2023187842A2 (en) * 2022-04-02 2023-10-05 Akseera Pharma Corp. Augmentation of anti-viral and anti-cancer treatments by combinations of poly(i:c) and cannabidiol
WO2024022478A1 (zh) * 2022-07-28 2024-02-01 长春金赛药业有限责任公司 结合大麻素受体cb1的抗体及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024742A (en) 1988-02-24 1991-06-18 Cedars-Sinai Medical Center Method of crosslinking amino acid containing polymers using photoactivatable chemical crosslinkers
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US6113940A (en) 1997-03-03 2000-09-05 Brooke; Lawrence L. Cannabinoid patch and method for cannabis transdermal delivery
US6328992B1 (en) * 1997-03-03 2001-12-11 Lawrence L. Brooke Cannabinoid patch and method for cannabis transdermal delivery
AU2001297913A1 (en) 2000-10-13 2002-12-23 Ligocyte Pharmaceuticals, Inc. Polyvalent nanoparticles
US20030049320A1 (en) * 2000-12-18 2003-03-13 Wockhardt Limited Novel in-situ forming controlled release microcarrier delivery system
CH695661A5 (de) * 2001-03-06 2006-07-31 Forsch Hiscia Ver Fuer Krebsfo Pharmazeutische Zusammensetzung.
EP1406576B2 (en) 2001-07-18 2011-06-29 Unilever PLC Hair and/or scalp treatment compositions
JP4851067B2 (ja) * 2004-01-28 2012-01-11 ホソカワミクロン株式会社 ナノ粒子含有組成物およびその製造方法
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
UA92498C2 (ru) * 2005-06-16 2010-11-10 Евро-Селтик С.А. Каннабиноидно активный фармацевтический ингредиент для улучшенных дозированных форм
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20100184848A1 (en) * 2006-07-14 2010-07-22 William Abraham Wine Transdermal formulations of synthetic cannabinoids and nano colloidal silica
US20080255224A1 (en) 2007-04-16 2008-10-16 Blum Richard S Pharmacological treatment of psoriasis
RU2503465C2 (ru) * 2008-12-19 2014-01-10 Ска Хайджин Продактс Аб Супервпитывающий полимерный композит, содержащий супервпитывающий полимер и целлюлозные нанофибриллы

Also Published As

Publication number Publication date
DK2729123T3 (en) 2016-01-11
EP2729123A2 (en) 2014-05-14
JP2014520817A (ja) 2014-08-25
US20140302121A1 (en) 2014-10-09
US8758826B2 (en) 2014-06-24
EP2729123A4 (en) 2014-08-20
MX2014000141A (es) 2015-03-20
EP2729123B8 (en) 2015-11-25
US20130011484A1 (en) 2013-01-10
WO2013006729A2 (en) 2013-01-10
WO2013006729A3 (en) 2014-05-08
EP2995302A1 (en) 2016-03-16
CA2840907C (en) 2018-09-11
KR20140065387A (ko) 2014-05-29
EP2729123B1 (en) 2015-10-14
CA2840907A1 (en) 2013-01-10
CN103796637A (zh) 2014-05-14

Similar Documents

Publication Publication Date Title
MX2014000141A (es) Agentes de enlace a receptor de canabinoide, composiciones y metodos.
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
AU2018253544A1 (en) Methods for treating or preventing asthma by administering an IL-4R antagonist
MX2011012196A (es) Composiciones y metodos para el suministro de farmaco.
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2021007794A (es) Composiciones y metodos para aplicaciones oftalmicas y/u otras aplicaciones.
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
MX2020007227A (es) Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2011008450A (es) Agonistas y antagonistas del receptor s1p5, y metodos de uso de los mismos.
MX368844B (es) Derivados de imidazolina, métodos de preparación de los mismos, y sus aplicaciones en medicina.
MX364637B (es) Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc.
IL223189B (en) Use of a preparation containing nanoparticles containing a taxane coated with albumin for the preparation of a drug for the treatment of pancreatic cancer
WO2011159769A3 (en) Indane estrogen receptor modulators and uses thereof
WO2011133925A3 (en) Targeted and light-activated cytosolic drug delivery
WO2011017690A3 (en) Intracellular delivery of contrast agents with functionalized nanoparticles
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
WO2012001065A3 (en) Use of alpha-adrenergic receptor agonist for preventing or treating skin tumor
WO2011087548A3 (en) Therapeutic compositions and methods for targeted delivery of active agents
MX2013008175A (es) Composiciones farmacéuticas para suministro tópico de fotosensibilizadores y usos de los mismos.
MX352176B (es) Proceso para producir un material inorganico particulado.
WO2012040331A3 (en) Multistage nanoparticles
MX339243B (es) Derivados fusionados sustituidos de imidazol, composiciones farmaceuticas y metodos de uso de los mismos.
PH12015502820A1 (en) Nanoparticulate formulation comprising a trpa1 antagonist
WO2012024634A3 (en) Environmentally-responsive nanocomposites and methods of their use

Legal Events

Date Code Title Description
FG Grant or registration